EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of hydroxyurea (hydroxycarbamide) in a national sickle cell disease programme in Ghana

Duah Dwomoh iD, Daniel Nana Yaw Abankwah, Amma A Benneh-Akwasi Kuma, Jonathan Quartey, Kwaku Marfo, Jonathan Spector, Etta Forson Addo, Olufolake Egbujo, Solomon Fiifi Ofori-Acquah, Kwaku Ohene-Frempong, Justice Nonvignon

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Duah Dwomoh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Ghana School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell, Antisickling Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxyurea (hydroxycarbamide; HU) has been shown to be a safe and effective drug for individuals living with sickle cell disease (SCD) in Africa. However, reports of large‐scale use of HU outside of controlled trial settings are limited on the continent. Access to HU in Ghana has improved through a major public–private partnership aimed at enhancing holistic care for communities affected by SCD. We evaluated the effectiveness of this programme through the measurement of biomarkers identified from health records, changes in clinical outcomes and quality of life (QoL) reported through interviews with participants and/or caregivers. The haemoglobin (Hb) levels of participants enrolled in the programme between September 2019 and July 2023 ( n = 1549) increased on average by 0.55 g/dL ( p < 0.001), with 9.2% of participants achieving Hb ≥10 g/dL. Six hundred participants and caregivers interviewed from April to November 2023 reported a significant reduction in the number of pain crises, malarial episodes, incidence of blood transfusions and rate of hospitalisations. Adults and children with SCD reported improved QoL in areas of physical, emotional, social and school‐related functioning. Lessons learned are expected to inform future efforts in Ghana and may support HU access programmes in other countries where SCD is highly endemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxyureaAnemia, Sickle CellAntisickling AgentsHumansGhanaFemaleAdultMaleQuality of LifeChildAdolescentMiddle AgedChild, PreschoolYoung Adult

Stichwörter der Autor:innen

Ghanahaemoglobinhydroxyurea (hydroxycarbamide)quality of lifesickle cell disease

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Department of Biostatistics, University of Ghana School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana.
  • Department of Health Policy Planning and Management, University of Ghana School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana.
  • Department of Haematology, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.
  • Department of Physiotherapy, University of Ghana School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana.
  • IQVIA Research and Development Solutions, Accra, Ghana.
  • Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Duah Dwomoh

Förderung

  • Novartis

Zitieren

APA

Dwomoh, D., Abankwah, D. N. Y., Benneh-Akwasi Kuma, A. A., Quartey, J., Marfo, K., Spector, J., Addo, E. F., Egbujo, O., Ofori-Acquah, S. F., Ohene-Frempong, K., & Nonvignon, J. (2025). Effectiveness of hydroxyurea (hydroxycarbamide) in a national sickle cell disease programme in Ghana. British Journal of Haematology. https://doi.org/10.1111/bjh.70079

Vancouver

Dwomoh D, Abankwah DNY, Benneh-Akwasi Kuma AA, Quartey J, Marfo K, Spector J, et al. Effectiveness of hydroxyurea (hydroxycarbamide) in a national sickle cell disease programme in Ghana. British Journal of Haematology. 2025. doi:10.1111/bjh.70079

BibTeX
@article{Dwomoh2025,
  author = {Dwomoh, Duah and Abankwah, Daniel Nana Yaw and Benneh-Akwasi Kuma, Amma A and Quartey, Jonathan and Marfo, Kwaku and Spector, Jonathan and Addo, Etta Forson and Egbujo, Olufolake and Ofori-Acquah, Solomon Fiifi and Ohene-Frempong, Kwaku and Nonvignon, Justice},
  title = {Effectiveness of hydroxyurea (hydroxycarbamide) in a national sickle cell disease programme in Ghana},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70079}
}
Kostenlos starten →